febuxostat has been researched along with mifepristone in 2 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (mifepristone) | Trials (mifepristone) | Recent Studies (post-2010) (mifepristone) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 6,536 | 595 | 1,758 |
| Protein | Taxonomy | febuxostat (IC50) | mifepristone (IC50) |
|---|---|---|---|
| Glucocorticoid receptor | Canis lupus familiaris (dog) | 0.0264 | |
| Bile salt export pump | Homo sapiens (human) | 2.02 | |
| Estrogen receptor | Homo sapiens (human) | 4.311 | |
| Glucocorticoid receptor | Homo sapiens (human) | 0.0249 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.0003 | |
| Progesterone receptor | Homo sapiens (human) | 0.1347 | |
| Glucocorticoid receptor | Rattus norvegicus (Norway rat) | 0.774 | |
| Glucocorticoid receptor | Mus musculus (house mouse) | 0.0022 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.0022 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 2.0938 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 9.5 | |
| Coagulation factor VII | Homo sapiens (human) | 0.0003 | |
| Androgen receptor | Homo sapiens (human) | 0.2988 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 1.5 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 4.9 | |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Rattus norvegicus (Norway rat) | 0.0016 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 0.555 | |
| Tissue factor | Homo sapiens (human) | 0.0003 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.0083 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0014 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.0022 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.0022 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 0.0078 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.0022 | |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | 0.0015 | |
| Mu-type opioid receptor | Homo sapiens (human) | 2.457 | |
| Estrogen receptor beta | Homo sapiens (human) | 1.528 | |
| Glucocorticoid receptor | Sus scrofa (pig) | 0.0153 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for febuxostat and mifepristone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for febuxostat and mifepristone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |